SCHEDULE: Armistice Capital Discloses 5.53% Stake in Promis Neurosciences
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 5.53% beneficial ownership in Promis Neurosciences Inc.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 2,974,518 common shares of Promis Neurosciences Inc.
- This ownership represents 5.53% of the company's common shares outstanding.
- The percentage is calculated based on 53,811,110 shares outstanding as of September 26, 2025.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is also deemed to beneficially own the shares.
- Both reporting persons hold shared voting and shared dispositive power over the 2,974,518 shares.
Sentiment
Score: 5
Explanation: This is a routine beneficial ownership disclosure (Schedule 13G Amendment) and does not contain information that inherently conveys positive or negative sentiment regarding the company's operational performance or future prospects. It is purely a factual update on an existing investment stake.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded company. It reflects an ongoing investment position rather than a new strategic move or operational update for Promis Neurosciences Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2025-09-26 | Date on which the number of shares outstanding (53,811,110) was reported by the Issuer on Form 14A. |
| 2025-09-30 | Date of event which required the filing of this statement. |
| 2025-11-14 | Date of signing and filing of the Schedule 13G Amendment No. 3. |
Keywords
Promis Neurosciences, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Shares, Investment Management, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.